129 related articles for article (PubMed ID: 38143493)
1. Discovery of potential WEE1 inhibitors via hybrid virtual screening.
Jin T; Xu W; Chen R; Shen L; Gao J; Xu L; Chi X; Lin N; Zhou L; Shen Z; Zhang B
Front Pharmacol; 2023; 14():1298245. PubMed ID: 38143493
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel wee1 inhibitors via structure-based virtual screening and biological evaluation.
Li Y; Pu Y; Liu H; Zhang L; Liu X; Li Y; Zuo Z
J Comput Aided Mol Des; 2018 Sep; 32(9):901-915. PubMed ID: 30182144
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
[TBL] [Abstract][Full Text] [Related]
4. Identification of Potential JNK3 Inhibitors: A Combined Approach Using Molecular Docking and Deep Learning-Based Virtual Screening.
Yao C; Shen Z; Shen L; Kadier K; Zhao J; Guo Y; Xu L; Cao J; Dong X; Yang B
Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895928
[TBL] [Abstract][Full Text] [Related]
5. Ensemble docking-based virtual screening toward identifying inhibitors against Wee1 kinase.
Li Y; Wu DM; Kong LM; Zhang S; Du H; Sun W; Zhang L; Li Y; Zuo Z
Future Med Chem; 2019 Aug; 11(15):1889-1906. PubMed ID: 31517534
[No Abstract] [Full Text] [Related]
6. Broadening the scope of WEE1 inhibitors: identifying novel drug candidates via computational approaches and drug repurposing.
Chandrasekaran J; Sivakumaresan Y; Shankar K; Dickson M; Laya Saravana Kumar S; Ramanathan L; Ahmad I; Patel H
J Biomol Struct Dyn; 2023 Aug; ():1-11. PubMed ID: 37632319
[TBL] [Abstract][Full Text] [Related]
7. Computational simulation studies on the binding selectivity of Wee1 and Checkpoint kinase 1 by molecular dynamics simulation combined with free energy calculations.
Li Y; Liu X; Zhang S; Wang L; Zhang L; Zuo Z
J Biomol Struct Dyn; 2022 Feb; 40(3):1172-1181. PubMed ID: 33016857
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer.
Seo HR; Nam AR; Bang JH; Oh KS; Kim JM; Yoon J; Kim TY; Oh DY
Cancer Res Treat; 2022 Apr; 54(2):541-553. PubMed ID: 34352995
[TBL] [Abstract][Full Text] [Related]
9. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
10. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.
Cuneo KC; Morgan MA; Davis MA; Parcels LA; Parcels J; Karnak D; Ryan C; Liu N; Maybaum J; Lawrence TS
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):782-90. PubMed ID: 26975930
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies.
Friedman J; Morisada M; Sun L; Moore EC; Padget M; Hodge JW; Schlom J; Gameiro SR; Allen CT
J Immunother Cancer; 2018 Jun; 6(1):59. PubMed ID: 29925431
[TBL] [Abstract][Full Text] [Related]
12. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
[TBL] [Abstract][Full Text] [Related]
13. Wee1 Inhibitor AZD1775 Effectively Inhibits the Malignant Phenotypes of Esophageal Squamous Cell Carcinoma
Bi S; Wei Q; Zhao Z; Chen L; Wang C; Xie S
Front Pharmacol; 2019; 10():864. PubMed ID: 31427973
[TBL] [Abstract][Full Text] [Related]
14. Development and Characterization of a Wee1 Kinase Degrader.
Li Z; Pinch BJ; Olson CM; Donovan KA; Nowak RP; Mills CE; Scott DA; Doctor ZM; Eleuteri NA; Chung M; Sorger PK; Fischer ES; Gray NS
Cell Chem Biol; 2020 Jan; 27(1):57-65.e9. PubMed ID: 31735695
[TBL] [Abstract][Full Text] [Related]
15. A hybrid energy-based and AI-based screening approach for the discovery of novel inhibitors of JAK3.
Wei J; Pan Y; Shen Z; Shen L; Xu L; Yu W; Huang W
Front Med (Lausanne); 2023; 10():1182227. PubMed ID: 37886358
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer.
Liu D; Cao Z; Xu W; Lin G; Zhou X; Ding X; Wang N; Wu C; Su B
Biomed Pharmacother; 2019 Sep; 117():109185. PubMed ID: 31387179
[TBL] [Abstract][Full Text] [Related]
17. Discovery of pyrido[4,3-d]pyrimidinone derivatives as novel Wee1 inhibitors.
Ye Q; Ma J; Wang P; Wang C; Sun M; Zhou Y; Li J; Liu T
Bioorg Med Chem; 2023 May; 87():117312. PubMed ID: 37167712
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore based virtual screening for identification of effective inhibitors to combat HPV 16 E6 driven cervical cancer.
Mohan A; Krishnamoorthy S; Sabanayagam R; Schwenk G; Feng E; Ji HF; Muthusami S
Eur J Pharmacol; 2023 Oct; 957():175961. PubMed ID: 37549730
[TBL] [Abstract][Full Text] [Related]
19. Discovery of pyrrolo[2,3-d]pyrimidine-based molecules as a Wee1 inhibitor template.
Chen C; Wang Y; Hu MQ; Li H; Chen X; Qiang G; Sun Y; Zhu Y; Li B
Bioorg Med Chem Lett; 2022 Nov; 75():128973. PubMed ID: 36075370
[TBL] [Abstract][Full Text] [Related]
20. Discovery of New Quinazoline Derivatives as VEGFR-2 Inhibitors: Design, Synthesis, and Anti-proliferative Studies.
Dhawale SA; Dabhade PS; Mokale SN
Anticancer Agents Med Chem; 2023; 23(18):2042-2055. PubMed ID: 37455449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
